Lyra Therapeutics, Inc.
LYRA
$0.0873
$0.00080.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -1.54% | 3.37% | 47.01% | 28.74% | 14.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.54% | 3.37% | 47.01% | 28.74% | 14.31% |
| Cost of Revenue | -8.88% | 2.59% | 23.66% | 23.13% | 23.80% |
| Gross Profit | 9.12% | -2.57% | -23.01% | -22.96% | -24.14% |
| SG&A Expenses | -2.92% | 21.05% | 21.42% | 9.14% | 8.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.18% | 7.16% | 23.06% | 19.03% | 19.05% |
| Operating Income | 7.32% | -7.24% | -22.57% | -18.82% | -19.16% |
| Income Before Tax | -49.14% | -58.11% | -66.57% | -15.48% | -13.31% |
| Income Tax Expenses | -33.90% | -9.09% | 51.28% | 118.52% | 353.85% |
| Earnings from Continuing Operations | -49.07% | -58.05% | -66.56% | -15.52% | -13.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.07% | -58.05% | -66.56% | -15.52% | -13.39% |
| EBIT | 7.32% | -7.24% | -22.57% | -18.82% | -19.16% |
| EBITDA | 7.24% | -7.80% | -23.73% | -20.26% | -20.48% |
| EPS Basic | -3.53% | 4.62% | 2.15% | 33.99% | 43.12% |
| Normalized Basic EPS | 33.98% | 34.08% | 26.67% | 34.50% | 43.71% |
| EPS Diluted | -3.53% | 4.62% | 2.15% | 33.99% | 43.12% |
| Normalized Diluted EPS | 33.98% | 34.08% | 26.67% | 34.50% | 43.71% |
| Average Basic Shares Outstanding | 38.58% | 62.08% | 64.33% | 73.45% | 87.56% |
| Average Diluted Shares Outstanding | 38.58% | 62.08% | 64.33% | 73.45% | 87.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |